Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Intercept Pharmaceuticals (ICPT)

Intercept Pharmaceuticals (ICPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,991,186
  • Shares Outstanding, K 32,696
  • Annual Sales, $ 179,800 K
  • Annual Income, $ -309,240 K
  • 60-Month Beta 1.32
  • Price/Sales 11.45
  • Price/Cash Flow N/A
  • Price/Book 11.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -2.33
  • Number of Estimates 11
  • High Estimate -1.44
  • Low Estimate -2.81
  • Prior Year -2.18
  • Growth Rate Est. (year over year) -6.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
58.21 +4.62%
on 08/05/19
68.86 -11.56%
on 07/25/19
-6.14 (-9.16%)
since 07/23/19
3-Month
58.21 +4.62%
on 08/05/19
88.58 -31.25%
on 05/24/19
-24.61 (-28.78%)
since 05/23/19
52-Week
58.21 +4.62%
on 08/05/19
133.74 -54.46%
on 10/01/18
-46.73 (-43.42%)
since 08/23/18

Most Recent Stories

More News
Intercept to Present at Upcoming Investor Conferences in September

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced...

ICPT : 60.90 (-3.30%)
Intercept Pharma Falls 5.22% on Heavy Volume: Watch For Potential Rebound

Intercept Pharma (NASDAQ:ICPT) traded in a range yesterday that spanned from a low of $63.76 to a high of $67.44. Yesterday, the shares fell 5.2%, which took the trading range below the 3-day low of...

ICPT : 60.90 (-3.30%)
Intercept Pharma Shares Down 32.9% Since SmarTrend's Sell Call (ICPT)

SmarTrend identified a Downtrend for Intercept Pharma (NASDAQ:ICPT) on April 12th, 2019 at $98.45. In approximately 4 months, Intercept Pharma has returned 32.90% as of today's recent price of $66.06....

ICPT : 60.90 (-3.30%)
Intercept Pharma Falls 1.92% on Heavy Volume: Watch For Potential Rebound

Intercept Pharma (NASDAQ:ICPT) traded in a range yesterday that spanned from a low of $63.21 to a high of $65.57. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of...

ICPT : 60.90 (-3.30%)
Downtrend Call Working As Intercept Pharma Stock Falls 33.0% (ICPT)

SmarTrend identified a Downtrend for Intercept Pharma (NASDAQ:ICPT) on April 12th, 2019 at $98.45. In approximately 4 months, Intercept Pharma has returned 33.02% as of today's recent price of $65.94....

ICPT : 60.90 (-3.30%)
Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus

Intercept (ICPT) posts a narrower-than-expected loss in Q2 and surpasses sales estimates.

GILD : 62.51 (-2.66%)
ICPT : 60.90 (-3.30%)
AMGN : 199.08 (-2.13%)
BIIB : 225.85 (-2.68%)
Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Tops Revenue Estimates

Intercept (ICPT) delivered earnings and revenue surprises of 9.16% and 12.21%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ICPT : 60.90 (-3.30%)
Intercept Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update

Company delivers strongest quarter to date with worldwide Ocalivanet sales of $65.9 million in the second quarter of 2019, representing 53% growth versus the prior year quarter

ICPT : 60.90 (-3.30%)
Intercept: 2Q Earnings Snapshot

NEW YORK (AP) _ Intercept Pharmaceuticals Inc. (ICPT) on Wednesday reported a loss of $71.4 million in its second quarter.

ICPT : 60.90 (-3.30%)
Intercept to Announce Second Quarter 2019 Financial Results on August 7, 2019

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce...

ICPT : 60.90 (-3.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade ICPT with:

Business Summary

Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR)....

See More

Key Turning Points

2nd Resistance Point 66.09
1st Resistance Point 63.49
Last Price 60.90
1st Support Level 59.37
2nd Support Level 57.85

See More

52-Week High 133.74
Fibonacci 61.8% 104.89
Fibonacci 50% 95.98
Fibonacci 38.2% 87.06
Last Price 60.90
52-Week Low 58.21

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar